Investigating the role of RIP kinases in inflammation and cell death related to type 2 diabetes
Novel roles for RIP kinases in islet inflammation and beta-cell cytotoxicity in type 2 diabetes
This study is looking at how a protein called RIPK3 affects inflammation and the health of insulin-producing cells in people with type 2 diabetes, and it aims to see if a special treatment can help protect these cells from damage.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rlr VA Medical Center NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11053851 on NIH RePORTER |
What this research studies
This research focuses on understanding how RIPK3, a protein involved in cell death, contributes to inflammation and the loss of insulin-producing beta cells in type 2 diabetes. By using a specialized mouse model, researchers will explore the mechanisms behind beta-cell dysfunction and how targeting RIPK3 with a small molecule inhibitor could potentially protect these cells. The study will involve advanced techniques such as RNA sequencing and live cell imaging to assess the effects of RIPK3 on inflammation and insulin secretion.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 2 diabetes who are experiencing beta-cell dysfunction.
Not a fit: Patients without type 2 diabetes or those with other forms of diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that protect beta cells and improve insulin function in patients with type 2 diabetes.
How similar studies have performed: Previous research has shown promising results in targeting RIPK3 for neurodegenerative diseases, suggesting potential for success in this novel approach for type 2 diabetes.
Where this research is happening
Indianapolis, United States
- Rlr VA Medical Center — Indianapolis, United States (Active)
Researchers
- Principal investigator: Templin, Andrew T. — Rlr VA Medical Center
- Study coordinator: Templin, Andrew T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.